# Epidemiology and Risk Prediction Model of Multidrug-Resistant Organism Infections After Liver Transplant Recipients: A Single-Center Cohort Study

**Authors:** Chuanlin Chen, Desheng Li, Zhengdon Zhou, Qinghua Guan, Bo Sheng, Yongfang Hu, Zhenyu Zhang

PMC · DOI: 10.3390/bioengineering12040417 · Bioengineering · 2025-04-14

## TL;DR

This study creates a model to predict multidrug-resistant infections in liver transplant patients using clinical factors like bilirubin and ICU stay.

## Contribution

A new nomogram model for predicting MDRO infections in liver transplant recipients using five clinical parameters is developed and validated.

## Key findings

- Five clinical factors (ascites, bilirubin, albumin, ICU history, and ICU length) were identified as predictors of MDRO infections.
- The model showed strong discrimination with an AUC of 0.88 in the training set and 0.77 in the validation set.
- The model's mean absolute error was 0.029, indicating high accuracy in predicting infection risk.

## Abstract

Objective: Accurate risk stratification at an early stage may reduce the incidence of infection and improve the survival rate of recipients by adopting targeted interventions. This study aimed to develop a nomogram to predict the risk of multidrug-resistant organism (MDRO) infections in liver transplant (LT) recipients. Methods: We retrospectively collected clinical data from 301 LT recipients and randomly divided them into a training set (210 cases) and validation set (91 cases) using a 7:3 split ratio. Factors related to the risk of MDRO infection after LT were determined using univariate and multivariate bidirectional stepwise logistic regression. The model’s predictive performance and discrimination ability were evaluated using receiver operating characteristic (ROC) curves, calibration curves, and decision curve analysis (DCA). Results: 56 (18.60%) patients developed a MDRO infection, including 37 (17.62%) in the training cohort and 19 (20.88%) in the validation cohort. Ultimately, five factors related to MDRO infection after LT surgery were established: ascites (OR = 3.48, 95% CI [1.33–9.14], p = 0.011), total bilirubin (OR = 1.01, 95% CI [1.01–1.01], p < 0.001), albumin (OR = 0.85, 95% CI [0.75–0.96], p = 0.010), history of preoperative ICU stay (OR = 1.09, 95% CI [1.01–1.17], p = 0.009), and length of ICU stay (OR = 3.70, 95% CI [1.39–9.84], p = 0.019). The model demonstrated strong discrimination, and the area under the curve (AUC), sensitivity, and specificity of the training set were 0.88 (95% CI [0.81–0.94]), 0.82 (95% CI [0.76–0.87]), and 0.86 (95% CI [0.75–0.98]), respectively, while for the validation set, they were 0.77 (95% CI [0.65–0.90]), 0.76 (95% CI [0.67–0.86]), and 0.68 (95% CI [0.48–0.89]). The mean absolute error (MAE) in the validation cohort was 0.029, indicating a high accuracy. DCA showed a clinical benefit within a threshold probability range of 0.1 to 0.7. Conclusions: This study developed a clinically accessible nomogram to predict the risk of MDRO infection in LT recipients, enabling early risk stratification and the real-time assessment of infection risk based on the length of postoperative ICU stay. The model incorporates five easily obtainable clinical parameters (ascites, total bilirubin, albumin, preoperative ICU stay history, and length of ICU stay) and demonstrates strong predictive performance, facilitating the early identification of high-risk patients. Future research should focus on refining the model by incorporating additional clinical factors (e.g., immunosuppressive therapy adherence) and validating its generalizability in multicenter, large-sample cohorts to enhance its clinical utility.

## Full-text entities

- **Genes:** ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}
- **Diseases:** MDRO infection (MESH:D018088), ascites (MESH:D001201), infection (MESH:D007239)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12024721/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12024721/full.md

## References

70 references — full list in the complete paper: https://tomesphere.com/paper/PMC12024721/full.md

---
Source: https://tomesphere.com/paper/PMC12024721